These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 23488622)

  • 1. Non-invasive molecular imaging for preclinical cancer therapeutic development.
    O'Farrell AC; Shnyder SD; Marston G; Coletta PL; Gill JH
    Br J Pharmacol; 2013 Jun; 169(4):719-35. PubMed ID: 23488622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.
    Wong MS; Sidik SM; Mahmud R; Stanslas J
    Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel drugs for promising targets.
    Martell RE; Brooks DG; Wang Y; Wilcoxen K
    Clin Ther; 2013 Sep; 35(9):1271-81. PubMed ID: 24054704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways.
    Xue N; Jin J; Liu D; Yan R; Zhang S; Yu X; Chen X
    Curr Cancer Drug Targets; 2014; 14(7):671-83. PubMed ID: 25219422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epothilone D (Kosan/Roche).
    Kolman A
    Curr Opin Investig Drugs; 2004 Jun; 5(6):657-67. PubMed ID: 15242255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical assessment of anti-cancer therapeutic strategies using in vivo videomicroscopy.
    Chambers AF; MacDonald IC; Schmidt EE; Morris VL; Groom AC
    Cancer Metastasis Rev; 1998-1999; 17(3):263-9. PubMed ID: 10352879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.
    Lee YC; Michael M; Zalcberg JR
    Expert Opin Investig Drugs; 2015; 24(10):1307-20. PubMed ID: 26212373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive Imaging for Assessment of the Efficacy of Therapeutic Agents for Hepatocellular Carcinoma.
    Liang Q; Kong L; Zhu X; Du Y; Tian J
    Mol Imaging Biol; 2020 Dec; 22(6):1455-1468. PubMed ID: 31834570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse tumour models to guide drug development and identify resistance mechanisms.
    Das Thakur M; Pryer NK; Singh M
    J Pathol; 2014 Jan; 232(2):103-11. PubMed ID: 24122209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic.
    Hoffman RM
    Invest New Drugs; 1999; 17(4):343-59. PubMed ID: 10759402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioluminescence imaging of invasive intracranial xenografts: implications for translational research and targeted therapeutics of brain tumors.
    Dinca EB; Voicu RV; Ciurea AV
    Neurosurg Rev; 2010 Oct; 33(4):385-94. PubMed ID: 20652720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions.
    Venditti JM; Wesley RA; Plowman J
    Adv Pharmacol Chemother; 1984; 20():1-20. PubMed ID: 6398966
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.
    Wang H; Han H; Mousses S; Von Hoff DD
    Semin Oncol; 2006 Aug; 33(4):513-20. PubMed ID: 16890805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Illuminating the metastatic process.
    Sahai E
    Nat Rev Cancer; 2007 Oct; 7(10):737-49. PubMed ID: 17891189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The problem of cancer dormancy: understanding the basic mechanisms and identifying therapeutic opportunities.
    Aguirre-Ghiso JA
    Cell Cycle; 2006 Aug; 5(16):1740-3. PubMed ID: 16929164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Journey of the ALK-inhibitor CH5424802 to phase II clinical trial.
    Latif M; Saeed A; Kim SH
    Arch Pharm Res; 2013 Sep; 36(9):1051-4. PubMed ID: 23700294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretation of treatment results with biological agents: is there a need for a new methodology?
    Begent RH
    J BUON; 2007 Sep; 12 Suppl 1():S53-8. PubMed ID: 17935278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy.
    Amoedo ND; Obre E; Rossignol R
    Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):674-685. PubMed ID: 28213330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
    Binkhathlan Z; Lavasanifar A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Learning from exceptional drug responders.
    Mullard A
    Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.